DR. ASHA KARIPPOT MD NPI 1841485216

NPI Details

DR. Asha Karippot, MD is a hematology and oncology internal medicine in Plano, TX with 24 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Asha Karippot, MD NPI is 1841485216. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

4708 ALLIANCE BLVD STE 150
PLANO, TX
ZIP 75093-339
Phone: (972) 596-7801
Fax: (972) 596-9307

The NPI 1841485216 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Magnesium level (HCPCS:83735)
• Phosphate level (HCPCS:84100)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Unclassified drugs (HCPCS:J3490)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Ct scan of chest with contrast (HCPCS:71260)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Reticulated (young) platelet measurement (HCPCS:85055)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev (HCPCS:G6013)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Ct scan of chest without contrast (HCPCS:71250)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Drawing of blood for a medical problem (HCPCS:99195)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)

The enumeration date for this NPI number is 9/10/2007 and was last updated on 9/23/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: